BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 25989802)

  • 1. The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy.
    Shim HJ; Shin MH; Kim HN; Kim JH; Hwang JE; Bae WK; Chung IJ; Cho SH
    Cancer Res Treat; 2016 Jan; 48(1):71-9. PubMed ID: 25989802
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Cho SH; Hong CS; Kim HN; Shin MH; Kim KR; Shim HJ; Hwang JE; Bae WK; Chung IJ
    Cancer Res Treat; 2017 Jul; 49(3):766-777. PubMed ID: 27857023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
    Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
    J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition.
    Ye Y; Li J; Jiang D; Li J; Xiao C; Li Y; Han C; Zhao C
    Cancer Res Treat; 2020 Oct; 52(4):1162-1177. PubMed ID: 32599983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma.
    Streit S; Bange J; Fichtner A; Ihrler S; Issing W; Ullrich A
    Int J Cancer; 2004 Aug; 111(2):213-7. PubMed ID: 15197773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma.
    Tanuma J; Izumo T; Hirano M; Oyazato Y; Hori F; Umemura E; Shisa H; Hiai H; Kitano M
    Oncol Rep; 2010 Mar; 23(3):739-44. PubMed ID: 20127014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.
    Ye Y; Shi Y; Zhou Y; Du C; Wang C; Zhan H; Zheng B; Cao X; Sun MH; Fu H
    Ann Surg Oncol; 2010 Dec; 17(12):3354-61. PubMed ID: 20844967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation.
    Whittle SB; Reyes S; Du M; Gireud M; Zhang L; Woodfield SE; Ittmann M; Scheurer ME; Bean AJ; Zage PE
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):131-8. PubMed ID: 26840079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor.
    Frullanti E; Berking C; Harbeck N; Jézéquel P; Haugen A; Mawrin C; Parise O; Sasaki H; Tsuchiya N; Dragani TA
    Eur J Cancer Prev; 2011 Jul; 20(4):340-7. PubMed ID: 21412156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients.
    Shen YY; Lu YC; Shen DP; Liu YJ; Su XY; Zhu GS; Yin XL; Ni XZ
    World J Gastroenterol; 2013 Jul; 19(28):4568-75. PubMed ID: 23901234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma.
    da Costa Andrade VC; Parise O; Hors CP; de Melo Martins PC; Silva AP; Garicochea B
    Exp Mol Pathol; 2007 Feb; 82(1):53-7. PubMed ID: 17084840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients.
    Streit S; Mestel DS; Schmidt M; Ullrich A; Berking C
    Br J Cancer; 2006 Jun; 94(12):1879-86. PubMed ID: 16721364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression.
    Wang J; Stockton DW; Ittmann M
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6169-78. PubMed ID: 15448004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung.
    Falvella FS; Frullanti E; Galvan A; Spinola M; Noci S; De Cecco L; Nosotti M; Santambrogio L; Incarbone M; Alloisio M; Calabrò E; Pastorino U; Skaug V; Haugen A; Taioli E; Dragani TA
    Int J Cancer; 2009 Jun; 124(12):2880-5. PubMed ID: 19296538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer.
    Sasaki H; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
    Oncol Rep; 2008 Nov; 20(5):1125-30. PubMed ID: 18949411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ECRG1 and FGFR4 single nucleotide polymorphism as predictive factors for nodal metastasis in oral squamous cell carcinoma.
    Choi KY; Rho YS; Kwon KH; Chung EJ; Kim JH; Park IS; Lee DJ
    Cancer Biomark; 2012-2013; 12(3):115-24. PubMed ID: 23481570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement.
    Quintanal-Villalonga Á; Carranza-Carranza A; Meléndez R; Ferrer I; Molina-Pinelo S; Paz-Ares L
    Clin Lung Cancer; 2017 Nov; 18(6):667-674.e1. PubMed ID: 28583379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homozygous GNAS 393C-allele carriers with locally advanced esophageal cancer fail to benefit from platinum-based preoperative chemoradiotherapy.
    Alakus H; Bollschweiler E; Hölscher AH; Warnecke-Eberz U; Frazer KA; Harismendy O; Lowy AM; Mönig SP; Eberz PM; Maus M; Drebber U; Siffert W; Metzger R
    Ann Surg Oncol; 2014 Dec; 21(13):4375-82. PubMed ID: 24986238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas.
    Wimmer E; Ihrler S; Gires O; Streit S; Issing W; Bergmann C
    World J Clin Oncol; 2019 Mar; 10(3):136-148. PubMed ID: 30949443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.
    Marmé F; Werft W; Benner A; Burwinkel B; Sinn P; Sohn C; Lichter P; Hahn M; Schneeweiss A
    Ann Oncol; 2010 Aug; 21(8):1636-1642. PubMed ID: 20147743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.